Navigation Links
Vital Therapies Expands SILVER Trial to Saudi Arabia
Date:9/16/2010

SAN DIEGO, Sept. 16 /PRNewswire/ -- Vital Therapies, Inc., (VTI) is pleased to announce that the first subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of Saudi Arabia (K.S.A.) in the further expansion of its SILVER (Stabilization In LiVER Failure) clinical trial to the Middle East. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).

The SILVER trial is an open label, multi center, controlled and randomized trial. To date, 40 subjects have been enrolled at 14 clinical sites in U.S. (11), U.K. (2) and K.S.A.  More than 20 sites should eventually enroll a total of 80 or more subjects in a 1:1 treated- to-control ratio.  If successful, the resulting data will provide the basis for a Biological License Application (BLA) in the U.S., a Marketing Approval Application (MAA) in Europe, and a marketing approval application in K.S.A. For a full listing of clinical trial sites and further information on the trial, please see www.clinicaltrials.gov.

National Guard Hospital in Riyadh is one of the few hospitals in the Middle East to be recognized for the conduct of multi-center international clinical trials. The Hospital has participated in several multinational clinical trials in the past.  The Principal Investigator in the trial, Dr. Ahmed Al Jabbary, said, "We are delighted to be a site for the SILVER clinical trial. Several of our nurses and physicians have been trained in the conduct of ELAD therapy at VTI's San Diego facility and are ready to assist in the subject treatments.  The logistics of the shipment of the live human liver cells in the ELAD cartridges have been addressed and we expect to be treating each subject within 36 hours of shipment of the cartridges from VTI's pl
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
2. Covidien Announces New Source of Vital Medical Isotopes
3. Blue Marble Energy, OPDA Awarded $2M by WAs Community Economic Revitalization Board
4. Pioneering research succeeds in producing industrially vital chemical through engineered bacteria
5. Scientists identify gene vital to early embryonic cells forming a normal heart and skull
6. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
7. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
8. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
9. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
10. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
11. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Log Sheets for Easily Locating Adhererent , Cells , ... , , , ... cells that have been used for microinjection. These sterile coverslips , ... protocol blocks , with the original microgrid patterns ...
... and Media for the Purpose of Plasmid , Isolation from ... > Perfectprep Plasmid Mini , ... , , , Joel Lopez, Melissa Higgins, Chere Griffin ... New York , Introduction , ...
... efficiencies in a variety of,transfection conditions ... Natalia Novoradovskaya ,Stratagene , Introducing foreign DNA ... superior quality transfection reagents that are,efficient, have ... or absence of serum. We,compared Stratagenes new ...
Cached Biology Technology:Comparison of Growth Techniques and Media for the Purpose of Plasmid , Isolation from E. coli Using the Eppendorf , Perfectprep Plasmid Mini , Kit 2Comparison of Growth Techniques and Media for the Purpose of Plasmid , Isolation from E. coli Using the Eppendorf , Perfectprep Plasmid Mini , Kit 3Comparison of Growth Techniques and Media for the Purpose of Plasmid , Isolation from E. coli Using the Eppendorf , Perfectprep Plasmid Mini , Kit 4High-Efficiency Transfections Achieved with New Low-Toxicity Reagent 2High-Efficiency Transfections Achieved with New Low-Toxicity Reagent 3High-Efficiency Transfections Achieved with New Low-Toxicity Reagent 4High-Efficiency Transfections Achieved with New Low-Toxicity Reagent 5
(Date:7/8/2015)... The consumer products industry for innovative ... products such as wearables, smart wallets & other smart technology ... devices continues to rapidly grow.  Biometrics & Wearable Device Companies ... Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: BIDU ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... body, particularly neuroproteins that maintain proper brain function. ... are known as "tangle diseases" because they are characterized ... brain. A team of Australian and American scientists ... be inserted into neuroproteins, causing them to misfold and ...
... world including science ministers from at least two nations ... September for a meeting that will explore new research and ... be held at the Sheraton Buenos Aires Hotel & Convention ... of science meetings from 1-4 October. Attendance is by invitation ...
... most extensively researched components in the diet. New studies ... of scientific research, which overall suggests that moderate habitual ... cardiovascular health Among recent studies, a new review ... consumption is unlikely to adversely affect cardiovascular health. Furthermore ...
Cached Biology News:New mechanism for protein misfolding may link to ALS 2TWAS to meet in dynamic Buenos Aires next week 2TWAS to meet in dynamic Buenos Aires next week 3
... 301 Power Supply, 1. 300 V, ... or constant current modes.Single-unit increments in ... reproducibility.Suitable for submarine, mini vertical, and ... as semidry and mini tank blotting ...
... Supply, 1. 1000 V, 400 mA, ... and constant power modes.Single-unit increments in ... reproducibility.Stores and recalls three protocols.Outstanding choice ... Multiphor II or GenePhor systems. ...
Mouse TrkC Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: